Sr Manager, Lung Portfolio Marketing
This job is no longer available
There are still lots of open positions. Let's find the one that's right for you.
About The Position
The Lung cancer portfolio is one of the fastest growing portfolios in Pfizer Oncology and includes the following brands: LORBRENA, BRAFTOVI/MEKTOVI Lung and XALKORI. Lung cancer is the most common cancer, and LORBRENA, our ALK+ inhibitor has been prescribed to over 12,000 patients since launching in the US in 2018. At ASCO 2024, the unprecedented 5-year follow analysis of the pivotal Phase 3 CROWN trial was presented and published. This practice-changing data is expected to solidify LORBRENA’s position in treating patients with ALK+ metastatic non-small cell lung cancer (NSCLC). BRAFTOVI+MEKTOVI is indicated for adult mNSCLC patients with a BRAF V600E mutation. Recent updates to the PHAROS study make this combination therapy also one of the growth drivers for the lung portfolio. The Sr Manager, Lung Portfolio Marketing position will report to the US Lung Team Lead and will be responsible for developing a variety of HCP and Patient strategies and tactics, including leading the planning and execution of congresses and speaker programs across the portfolio. Activities associated with this position include strategic marketing, tactics planning, data & analytics. The Sr Manager will work closely with internal and external partners, including, sales, market insights, Regulatory, Legal, Medical Affairs, TLELs, Advocacy, other members of the brand team, and agencies.
